Aptiv price prediction for 7/19


Aime
Aptiv's stock price is likely to face downward pressure in the short term, with a potential drop from its current price of $69.44 to $56.75, representing a -19.28% change1. This forecast is based on historical data and market trends, which suggest that the stock may continue to experience volatility.
- Analyst Price Targets:
- The average 12-month price target from 9 Wall Street analysts is $105.14, with a high forecast of $145.00 and a low of $83.002.
- Another set of 12-month price targets from 11 analysts has an average of $111.33, with a low estimate of $74 and a high estimate of $1453.
- Short-term price targets from 17 analysts give an average of $101.124.
average price target(6176)average price target rank from largest to smallest 1(1)
last-price | last-change% | Average Price Target(USD)2024.07.01 | Average Price Target rank2024.07.01 |
---|---|---|---|
7.46K | -0.29% | 8K | 1/6176 |
Ticker |
---|
NVRNVR |
View 1 result
- Market Sentiment:
- The stock has experienced a recent sell candidate since June 14, 2024, and has seen a -17.15% decline in four weeks5.
- There is a mixed signal from the short-term and long-term moving averages, with a buy signal from the former and a sell signal from the latter6.
market cap(6178)market cap rank from largest to smallest 2(2)
last-price | last-change% | Market Cap(USD)2024.07.02 | Market Cap rank2024.07.02 |
---|---|---|---|
459.28 | 0.56% | 3413.51B | 1/6176 |
220.27 | 1.62% | 3377.64B | 2/6176 |
Ticker |
---|
MSFTMicrosoft |
AAPLApple |
View 2 results
- Technical Indicators:
- The stock's 52-week range is $45.578 to $113.6, and the 200-day moving average is $79.551.
- The stock is currently trading below its 90-day and 200-day moving averages1.
indication(145)
last-price | last-change% | Indication | Drug Name | FDA Review Round | Accelerated Approval Status | Accelerated Approval Pathway | FDA Approval Status | FDA Approval Event Type | FDA Review Date |
---|---|---|---|---|---|---|---|---|---|
0.96 | -3.42% | Chronic kidney disease, Anemia, Kidney disease | Vafseo(Vadadustat) | 1 | Not Accelerated | -- | Approved | PDUFA Date | 20240327 |
0.96 | -3.42% | Anemia, Chronic kidney disease, Kidney disease | Vafseo (Vadadustat) | 1 | Not Accelerated | -- | Pending | PDUFA Date | 20240327 |
3.25 | 0.00 | Dry eye syndrome | Reproxalap | 1 | Not Accelerated | -- | Complete Response Letter | PDUFA Date | 20231127 |
3.25 | 0.00 | Eye disease , Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Proliferative vitreoretinopathy | ADX-2191 (DHFR inhibitor) | 1 | Accelerated | Priority Review | Pending | PDUFA Date | 20230621 |
247.61 | 1.76% | Transthyretin amyloidosis | ONPATTRO (Patisiran) | 1 | Not Accelerated | -- | Pending | PDUFA Date | 20231008 |
247.61 | 1.76% | Transthyretin amyloidosis | ONPATTRO (Patisiran) | 1 | Not Accelerated | -- | Pending | FDA Adcomm | 20230913 |
310.77 | -0.08% | KRAS G12C-POSITIVE NSCLC | LUMAKRAS/LUMYKRAS | 1 | Accelerated | Accelerated Approval | Complete Response Letter | PDUFA Date | 20231226 |
310.77 | -0.08% | Non-small cell lung carcinoma | LUMAKRAS/LUMYKRAS Copy | 1 | Accelerated | Accelerated Approval | Pending | FDA Adcomm | 20231005 |
310.77 | -0.08% | Small cell lung cancer, Lung cancer, Cancer | Tarlatamab (AMG 757) | 1 | Accelerated | Priority Review | Approved | PDUFA Date | 20240516 |
310.77 | -0.08% | B-cell acute lymphoblastic leukemia | BLINCYTO(blinatumomab) | 1 | Accelerated | Priority Review | Approved | PDUFA Date | 20240621 |
6.54 | 1.87% | Parkinson disease | IPX203 | 1 | Not Accelerated | -- | Pending | PDUFA Date | 20230630 |
23.94 | -2.72% | Recurrent or Advanced dMMR/MSI-H Endometrial Cancer | JEMPERLI (dostarlimab-gxly) | 1 | Not Accelerated | -- | Pending | PDUFA Date | 20230923 |
2.42 | -1.22% | Seizures | LIBERVANT(Diazepam) Buccal Film | 1 | Not Accelerated | -- | Approved | PDUFA Date | 20240429 |
5.28 | -30.25% | Electrolyte disorder, Hyperphosphatemia, Kidney disease, Chronic kidney disease | XPHOZAH (Tenapanor) (Phosphate Absorption Inhibitor) | 1 | Not Accelerated | -- | Pending | PDUFA Date | 20231017 |
435.49 | 0.29% | MYASTHENIA GRAVIS, Autoimmune disease | SC Efgartigimod | 1 | Not Accelerated | -- | Pending | PDUFA Date | 20230620 |
435.49 | 0.29% | Chronic inflammatory disorder | VYVGART Hytrulo (Efgartigimod) | 1 | Accelerated | Priority Review | Approved | PDUFA Date | 20240614 |
9.30 | -2.72% | Skin disease/disorder, Seborrheic dermatitis | Roflumilast foam 0.3% | 1 | Not Accelerated | -- | Approved | PDUFA Date | 20240405 |
9.30 | -2.72% | Atopic dermatitis | ARQ-151 topical roflumilast cream (PDE4 Inihibitor) | 1 | Not Accelerated | -- | Pending | PDUFA Date | 20240707 |
Ticker |
---|
AKBAAkebia Therapeutics |
AKBAAkebia Therapeutics |
ALDXAldeyra Therapeutics |
ALDXAldeyra Therapeutics |
ALNYAlnylam Pharmaceuticals |
ALNYAlnylam Pharmaceuticals |
AMGNAmgen |
AMGNAmgen |
AMGNAmgen |
AMGNAmgen |
AMRXAmneal |
ANABAnaptysBio |
AQSTAquestive |
ARDXArdelyx |
ARGXargenx |
ARGXargenx |
ARQTArcutis |
ARQTArcutis |
View 79 results
- Future Outlook:
- The stock is considered undervalued by some analysts, with an intrinsic value of $114.807.
- However, the stock's beta suggests that it may face exaggerated price declines in a bearish market7.
4.'s future policy benefits(6176)
last-price | last-change% | Future Policy Benefits(USD)2022.09.30 | Future Policy Benefits(USD)2022.12.31 | Future Policy Benefits(USD)2023.03.31 | Future Policy Benefits(USD)2023.06.30 | Future Policy Benefits(USD)2023.09.30 | Future Policy Benefits(USD)2023.12.31 | Future Policy Benefits(USD)2024.03.31 | Future Policy Benefits(USD)2024.06.30 |
---|---|---|---|---|---|---|---|---|---|
118.55 | 0.87% | 278.26B | 261.77B | 273.59B | 268.65B | 253.55B | 273.28B | 272.79B | -- |
26.43 | 0.49% | 271.18B | 269.68B | 279.78B | 278.85B | 262.29B | 287.69B | 282.95B | -- |
70.04 | 0.23% | 199.67B | 187.22B | 191.74B | 190.47B | 181.76B | 196.41B | 191.01B | -- |
407.10 | 0.47% | 150.61B | 162.64B | 162.96B | 163.09B | 162.30B | 165.94B | 163.71B | -- |
610.67K | 0.03% | 150.61B | 162.64B | 162.96B | 163.09B | 162.30B | 165.94B | 163.71B | -- |
75.33 | 1.13% | 132.79B | 127.08B | 130.64B | 125.97B | 121.49B | 128.97B | 129.05B | -- |
48.96 | 0.49% | 100.30B | 97.02B | 99.25B | 97.57B | 92.26B | 102.76B | 99.64B | -- |
255.57 | 0.29% | 85.58B | 86.22B | 86.20B | 87.54B | 92.81B | 94.01B | 94.72B | -- |
89.43 | 0.42% | 79.15B | 88.44B | 91.52B | 86.15B | 78.70B | 83.98B | 78.21B | -- |
29.59 | 1.61% | 55.41B | 50.52B | 53.41B | 54.29B | 50.36B | 57.11B | 57.59B | -- |
Ticker |
---|
PRUPrudential Financial |
MFCManulife Financial |
METMetLife |
BRK.BBerkshire Hathaway B |
BRK.ABerkshire Hathaway A |
AIGAmerican |
SLFSun Life Financial |
CBChubb |
AFLAflac |
CRBGCorebridge Financial |
View 6176 results
Given these points, while there is potential for growth in the long term, based on the average price targets and intrinsic value estimates, the short-term outlook seems cautious due to recent sell signals and the potential for market volatility. Investors should consider these factors when making investment decisions for Aptiv.
Source:
w
1.
Aptiv Stock Forecast, "APTV" Share Price Prediction Charts
more
less
Continue this conversation 

For you
Explore
Screener
Analysis
Learn
Wiki